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SObjective: We sought to determine the relative contributions of epithelial cells and mesenchymal stem cell–de-
rived chondrocytes to the survival of tissue-engineered airway transplants in pigs.
Methods: Nonimmunogenic tracheal matrices were obtained by using a detergent-enzymatic method. Major his-
tocompatibility complex–unmatched animals (weighing 65  4 kg) were divided into 4 groups (each n ¼ 5), and
6 cm of their tracheas were orthotopically replaced with decellularized matrix only (group I), decellularized ma-
trix with autologous mesenchymal stem cell–derived chondrocytes externally (group II), decellularized matrix
with autologous epithelial cells internally (group III), or decellularized matrix with both cell types (group IV).
Autologous cells were recovered, cultured, and expanded. Mesenchymal stem cells were differentiated into chon-
drocytes by using growth factors. Both cell types were seeded simultaneously with a dual-chamber bioreactor.
Animals were not immunosuppressed during the entire study. Biopsy specimens and blood samples were taken
from recipients continuously, and animals were observed for a maximum of 60 days.
Results: Matrices were completely covered with both cell types within 72 hours. Survival of the pigs was signif-
icantly affected by group (P<.05; group I, 11  2 days; group II, 29  4 days; group III, 34  4 days; and group
IV, 60  1 days). Cause of death was a combination of airway obstruction and infection (group I), mainly infec-
tion (group II), or primarily stenosis (group III). However, pigs in group IV were alive, with no signs of airway
collapse or ischemia and healthy epithelium. There were no clinical, immunologic, or histologic signs of rejection
despite the lack of immunosuppression.
Conclusions:We confirm the clinical potential of autologous cell– and tissue-engineered tracheal grafts, and sug-
gest that the seeding of both epithelial and mesenchymal stem cell–derived chondrocytes is necessary for optimal
graft survival. (J Thorac Cardiovasc Surg 2010;139:437-43)Long-segment airway stenosis is life-threatening, but pres-
ent surgical options are not ideal.1 A tracheal graft suitable
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The Journal of Thoracic and Caflexibility, strength to avoid collapse, and formation of air-
tight seals.2,3 It should not excite a rejection response and
promote cell adhesion and growth, including angiogenesis.
Such an ideal construct has proved elusive and difficult to
reproduce.4–7 We recently performed the world’s first stem
cell–based, fully tissue-engineered tracheal graft, which
has been a success to date.8 However, before we used the
graft in human subjects, we evaluated the relative contribu-
tion of the autologous biopsy-derived epithelial cells and
mesenchymal stem cell (MSC)–derived chondrocytes for
the survival of seeded decellularized scaffolds when implant-
ing them orthotopically in pigs. Results are presented here.MATERIALS AND METHODS
Thirty Yorkshire Duroc pigs (Isoquimen S/L, Barcelona, Spain)
weighing 65  4 kg were used. All animals received care in compliance
with the ‘‘Principles of laboratory animal care’’ formulated by the Na-
tional Society for Medical Research and the ‘‘Guide for the care and
use of laboratory animals’’ prepared by the Institute of Laboratory Ani-
mal Resources, National Research Council, and published by the National
Academy Press, revised 1996. This study was approved by the Animal
Care and Use Committee and the Bioethics Committee of the University
of Barcelona.rdiovascular Surgery c Volume 139, Number 2 437
Abbreviations and Acronyms
DM ¼ decellularized matrix
MHC ¼ major histocompatibility complex
MSC ¼ mesenchymal stem cell
PBS ¼ phosphate-buffered saline





The entire trachea (median length, 12 cm) was retrieved from 10 donors.
Tracheal matrices were engineered according to our published method.8–10
Bone marrow–derived MSCs and mucosal epithelial cells were obtained
from the intended recipients (n ¼ 20) by means of bone marrow aspiration
followed by expansion and differentiation, as previously described, bron-
chial biopsy, respectively.8 Recipients were randomly (computer-generated
code) divided into 4 groups of 5 animals, and 6 cm of their tracheas was re-
placed with decellularized matrix (DM) only (group I); DM with external,
autologous MSC-derived chondrocytes (group II); DM with internal, autol-
ogous epithelial cells (group III); or DM seeded with both cell types (group
IV). Biopsy specimens and blood samples were continuously taken from re-
cipients, and animals were observed for a maximum of 60 days. Tracheas
were harvested and evaluated postmortem.
Anesthesia: Tracheal Harvesting From Donors and
Autologous Cell Isolation From Recipients
Animals (n ¼ 10) were premedicated with azaperone (4 mg/kg adminis-
tered intramuscularly; Esteve S.A., Barcelona, Spain) and intravenous thio-
pental injection (10 mg/kg; B. Braun Medical S.A., Rubi, Barcelona, Spain)
and relaxed with intravenous vecuronium (Norcuron; 6 mg $ kg1 $ h1; Or-
ganon S.A., Barcelona, Spain). Orotracheal intubation was obtained with
a 7.5F or 8F endotracheal tube. Anesthesia was maintained with fentanyl
(1 mg $ kg1 $ h1, B. Braun Medical S.A.) and propofol (3–5 mg $ kg1 $
h1, B. Braun Medical S.A.) intravenous infusions. A pulse oximeter (BCI,
Inc, Waukesha, Wis) placed at the pig’s tail was used to measure the arterial
oxygen saturation. For retrieval, a median cervicosternotomy was performed
to dissect the trachea in its entirety.7,8,10 Thereafter, animals were killed with
an intravenous bolus of fentanyl, propofol, and potassium chloride (40 mEq;
B. Braun, Melsungen, Germany). The entire tracheas were taken (12 cm) and
then divided into 2 parts of 6 cm each and stored in a stock solution made of
phosphate-buffered saline (PBS; Invitrogen S.A., Barcelona, Spain) contain-
ing 1% antibiotic and antimycotic solution (Sigma Chemical Co, Barcelona,
Spain). Future graft recipients were anesthetized similarly. Cell populations
were obtained by means of a single 80-mL aspiration of bone marrow from
the crista iliaca and tracheal endoscopic epithelial biopsy specimens, and
maximal attention was paid to isolate cells under completely sterile condi-
tions to avoid cell-culture contamination. After sample harvesting, weaning
was induced, and animals were extubated, with time to recover.
Matrix Bioengineering
Matrix bioengineering followed our previously published method.8–10
Briefly, tracheas were incubated with multiple treatment cycles, including
Aqua milliQ (Millipore, Madrid, Spain) storage for 48 hours at 4C, and
then incubated in 4% sodium deoxycholate and 2000 kU DNase-I (Sigma
Chemical Co), respectively, for 3 hours. After 17 cycles, which was the pre-
viously determined optimum point for loss of antigenicity but preservation
of biomechanical strength,10 samples were examined to check for the ab-
sence of intact cells and major histocompatibility complex (MHC) expres-
sion. Finally, tracheas were then stored in PBS at 4C until use.
Autologous Cell Isolation and Culture
MSCs were isolated by purifying the aspirated bone marrow through
a previously prepared Percoll (Sigma Chemical Co) gradient (1:9 Percoll/438 The Journal of Thoracic and Cardiovascular SurgNaCl). Bone marrow was centrifuged at 500g (relative centrifugal force) at
4C, and the thin, bright cell layer was gently removed. Counted cells were
seeded at a density of 1.1 3 106/mL with complete medium (Dulbecco’s
modified Eagle’s medium containing 1000 mg L-glucose, Sigma-Aldrich),
10% fetal bovine serum (Biological Industries, Beit Haemek, Israel), 100
U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L GlutaMax-I
(Invitrogen) with 5 ng/mL basic fibroblast growth factor (PeproTech,
London, United Kingdom). Cells were used for differentiation, reaching 3
to 4 passages. According to a standard cell-culture protocol, differentiation
was induced by adding 10 ng/mL recombinant human transforming growth
factor b 3 (R&D Systems, Abingdon, United Kingdom), 10 nmol/L recombi-
nant parathyroid-related peptide (PeproTech), 100 nmol/L dexamethasone,
and 10 mg/mL insulin (both Sigma-Aldrich) and incubating for 72 hours.
There were no fibroblasts detected before seeding the tracheal matrix.
Epithelial biopsy specimens were incubated with 0.25% trypsin–ethyle-
nediamine tetraacetic acid (Gibco, Prat de Llobregat, Spain) overnight at 4C
and the next morning for 45 minutes at 37C. The mixture was then neutral-
ized with complete medium (containing fetal bovine serum), and the liquid
was removed and transferred to a new tube. Thereafter, liquid was centri-
fuged at 1000 rpm for 10 minutes, supernatant was removed, and the pellet
was resuspended. Obtained cells were then transferred to small flasks and
cultured with a specific airway epithelial cell growth medium (PromoCell;
Lab S.A., Barcelona, Spain) containing 13 mg/1 mL bovine pituitary extract,
5.0 mg/500 mL human recombinant epidermal growth factor, 250.0 mg/500
mL epinephrine, 250.0 mg/500 mL hydrocortisone, 2.5 mg/500 mL recombi-
nant human insulin, 50.0 ng/500mL retinoic acid, 5.0 mg/500mL transferrin,
and 3.35 mg/500 mL tri-iodo-L-thyronine in 500 mL. The cell culture was
performed according to a standard protocol. However, Hanks buffered salt
solution (Sigma) was used when removing cells. Cells were used for seeding
at the point at which they reached 4 to 5 passages. Both cell lines were sep-
arately seeded on the pre-engineered matrices by using a dedicated, dual-
chamber bioreactor. The device provided continuous rotation of the graft, ex-
posing cells to a covering film of alternating gas and liquid phases.
Histology and Immunochemistry
Tracheas were analyzed before transplantation and after harvesting.
Samples were washed thoroughly in saline before use. To quantify the re-
maining cells after each cycle of the detergent-enzymatic method treatment,
we analyzed tissues according to our protocol. Briefly, nuclei were visual-
ized with 40-6-diamidino-2-phenylindole (Vector Laboratories, Inc, Burlin-
game, Calif), and cell density was determined. Paraffin-embedded tissue
sections measuring 5 mm were mounted on slides and stained with hematox-
ylin and eosin (Merck, Darmstadt, Germany) to evaluate morphologic
changes. The presence of MHC markers was evaluated by means of immu-
nostaining with monoclonal anti-MHC class I OX27 and anti-MHC class II
OX4 antibodies (Abcam, Cambridge, United Kingdom).
Physical Strain Tests
Bioengineered matrices from each group were tested by using a previ-
ously published method10 based on a tensile-test device (Zwick/Roell, ver-
sion Z0.5TS; Barcelona, Spain). Each sample was subjected to increasing
uniaxial tensile testing until rupture, which was confirmed by the loss of
load and the appearance of tears in the tissue. The specimens were clamped
into sample holders, a preload (preliminary force) of 2 N was applied, and
the trial was started at a constant elongation rate of 1 mm/s at room temper-
ature. The tensile tester recorded the load and elongation to which the tissue
was subjected in real time.Orthotopic Graft Transplantation and Postoperative
Observation
The graft transplantation was performed according to our previously de-
scribed method.6,7,11 Briefly, after general anesthesia was achieved, recipi-
ents’ tracheas were exposed through an anterior midline cervical incision.ery c February 2010
FIGURE 1. A, Mesenchymal stem cells in vitro cultured after isolating with Percoll from bone marrow aspirate. B, Mesenchymal stem cell pellet after cen-
trifugation at 1000 rpm for 5 minutes. Standard method for chondrocyte differentiation: culture cells with 10 ng/mL recombinant human transforming growth
factor b3. C, Immunohistostaining of mesenchymal stem cells not treated with 10 ng/mL transforming growth factor b3 as a negative control. No collagen type
II was detected. D, Immunohistostaining for collagen type II detected after 21 days with transforming growth factor b3.




SThen the sternohyoid muscles were divided and the cervical fat lobe was dis-
sected. We opened the pretracheal fascia, mobilized the intrathoracic tra-
chea, and placed traction sutures to retract it superiorly. The endotracheal
tube was pulled back into the subglottic larynx, and 10 to 12 tracheal rings
(6 cm) of the recipients’ cervical tracheas were excised and replaced with the
tissue-engineered graft. At least 2 tracheal rings below the cricoid were left
in place to anastomose the tracheal graft. The anastomoses were made with
a 4–0 continuous polydiaxone (Ethicon, Inc, Somerville, NJ) parachute su-
tures of the posterior membranous wall and 5–0 absorbable polygalactin
(Vicryl; Ethicon, Inc) interrupted sutures on the anterolateral anastomosis,
with knots tied extraluminally. Gas exchange during performance of the
anastomoses was through apneic hyperoxygenation. The skin was closed
in the usual fashion. Postoperatively, antibiotics (cefazolin, 2 g/d adminis-
tered intravenously; Lilly, Madrid, Spain) and analgesics (Enantyum
[dexketoprofen], 40 mg/12 h; Menarini, Barcelona, Spain) were adminis-
tered intravenously for the first 7 days. Animals were placed in cages and
fed standard laboratory pig food and water ad libitum. They were examined
daily for 60 days or until death, if earlier, for clinical signs of inflammation
or rejection and for general health. Blood samples were taken weekly to
check for the development of antibodies and increased inflammatory
response. The presence of bacteria and fungi before and after implantation
was determined by means of conventional microbiologic techniques
performed on small, fresh tissue biopsy specimens.
Analysis of Tissue From Pig Recipients
Samples were formalin fixed and paraffin embedded before staining with
hematoxylin and eosin (Merck). Anti–swine leukocyte antigen antibodies
were tested at 7, 15, 23, and 30 days after matrix implantation by using
a modification of the standard flow cytometric crossmatch on lymph node
cells, as previously described.10 Briefly, donor pig lymph node cells were
incubated for 30 minutes with recipient serum and rinsed 3 times in PBS,The Journal of Thoracic and Caand a fluorescein-marked anti-porcine immunoglobulin and phycoery-
thrin–marked anti-porcine CD3 was added for 30 minutes. A FACS scan
(FACS Aria; Becton–Dickinson, Erembodegem, Belgium) was used to
evaluate the double fluorescence. The coefficient between the mean channel
in test serum in negative control serum for T cells (defined by mentioned
double fluorescence) was recorded. We considered a ratio of greater than
2.9 to be positive based on previous samples obtained before implantation.
Immunochemistry was performed with a rabbit anti-CD3 antibody (Dako,
Glostrup, Denmark) and mouse anti-L1 antibody (Dako), respectively, to
identify T lymphocytes, monocytes/macrophages, and polymorphonuclear
granulocytes.
Statistical Analysis
Continuous variables were compared by using the independent-samples t
test. The odds ratio was calculated to perform comparisons of categorical
variables in between groups. Results are presented as the mean  standard
deviation of the mean. SPSS software was used (version 12.0; SPSS, Inc,
Chicago, Ill). Statistical significance was accepted at the 5% level.RESULTS
All bioengineered matrices were negatively stained for
both MHC I and II. MSCs could be isolated from bone mar-
row aspiration and differentiated into chondrocytes
(Figure 1). Epithelial cells were easily obtained by means
of tracheal biopsy followed by cell culture (Figure 2, A
and B). The bioengineered matrices were seeded through
the bioreactor (Figure 2, D) to near confluence by 72 hours
(Figure 3). There was no evidence of contamination onrdiovascular Surgery c Volume 139, Number 2 439
FIGURE 2. A, Epithelial in vitro cell culture after 3 days. B. Epithelial in vitro cell culture after 14 days. C, Tensile-test device evaluating the bioengineered
graft. D, Engineered matrix fixed to the bioreactor before starting the seeding process.




Sbacteriologic analysis before implantation. Over the study
period, the implanted graft did not elicit any rejection re-
sponse, such as swine leukocyte antigen, and this was with-
out immunosuppression. Orthotopically transplantedFIGURE 3. Scanning electron microscopic images at different amplifications s
cations are shown.
440 The Journal of Thoracic and Cardiovascular Surgnonseeded matrices (group I) led to high-grade stenosis
(50%–75% decrease in diameter) and bacterium/fungus-
contaminated inner surface. The external seeding of MSC-
derived chondrocytes (group II) resulted in a quite stablehowing seeded matrices (after 72 hours of seeding time). Different amplifi-
ery c February 2010
FIGURE 4. The first column shows formalin-embedded macroscopic views (transversal sections, group specific). The second (1003) and third (2003) col-
umns display a microscopic view of hematoxylin and eosin histologic transversal sections (group specific). For group I (decellularized matrix only), both
stenosis and the inflammatory process are visible. For group II (decellularized matrix with external, autologous mesenchymal stem cell–derived chondro-
cytes), less stenosis but a high grade of bacterial/fungal contamination is shown. For group III (decellularized matrix with internal, autologous epithelial cells),
less inflammatory signs and no bacterial/fungal contamination are shown (high stenosis caused by weakness). For group IV (decellularized matrix with both
cell types), no stenosis or contamination is shown.




S(25%–50% decrease in diameter) but highly contaminated
graft. Grafts seeded only with epithelial cells on the inner
surface (group III) also showed high-grade stenosis
(>75%), apparently caused by malacia but without bacte-
rial/fungal contamination. Only seeding both sides of the
matrices resulted in a healthy functional graft (<25% de-
crease in diameter, Figure 4), and only slight postoperative
inflammatory signs were detected. The histologic and mac-
roscopic findings correlated with the animals’ clinical out-
come. With respect to the time point of the pigs’ death,
only group IV animals remained healthy enough to avoid
death before the 60-day censor point. All other animals
were killed significantly earlier because of signs of markedTABLE 1. Comparison of the mechanical characteristics of native and bio
Characteristics Native trachea I
Mechanical
Maximum force (N) 182.0  5.1 58.1  8.8
Rupture force (N) 58.3  2.9 24.4  4.7
Tracheal rupture point (cm) 12.1  0.4 7.3  0.4
Tissue deformation (%) 202  7 121  7*
The term native trachea represents natural untreated tracheas harvested from healthy anima
autologous mesenchymal stem cell–derived chondrocytes; group III, decellularized matrix
both cell types; Maximum force, applied maximum force. *P< .01 versus native trachea. y
The Journal of Thoracic and Carespiratory distress not amenable to simple treatment mea-
sures (group I, 11 2 days; group II, 29 4 days; and group
III, 34  4 days). Preimplantation strain tests (Figure 2, C)
showed no significant difference between the graft and the
native trachea, as demonstrated before.10 However, postop-
eratively retrieved grafts from groups I to III, but not group
IV, showed a statistically lower resilience (Table 1).
DISCUSSION
Our recent first in a human subject experience with a re-
seeded, decellularized tracheal graft8 was based on the find-
ings described here. This experimental study explored the
biologic mechanisms underlying the success of theengineered tracheas (retrieved postmortem)
Bioengineered grafts (postmortem), groups
II III IV
* 87.5  6.6* 60.4  8.7* 174.8  7.7y
* 32.7  3.7* 24.2  5.2* 55.6  2.6y
* 7.9  0.3 * 7.9  0.9* 11.9  0.4y
132  5* 132  14* 198  7y
ls. Group I, Decellularized matrix only; group II, decellularized matrix with external,
with internal, autologous epithelial cells; group IV, decellularized matrix seeded with
P> .05 versus native trachea.
rdiovascular Surgery c Volume 139, Number 2 441




Stransplanted tissue-engineered graft. The first question we
wished to answer was as follows: What is the relative contri-
bution of the 2 cell types seeded onto the scaffold, and were
both cell types necessary for graft and recipient survival?
The study confirmed the applicability of the decellulariza-
tion, cell preparation, and reseeding techniques, as well as
the ease of application of our tracheal bioreactor. However,
attention should be paid during cell isolation and culture to
avoid contamination caused by fibrocyte proliferation. Nota-
bly, no animal demonstrated the development of local or sys-
temic rejection responses to any residual donor antigens, and
this was without the administration of immunosuppressive
medication. Zani and colleagues12 demonstrated in 2008
the potential of tissue healing and functional restoration if
epithelial and endothelial cells are present at the same
time, even with a lack of an ordered architectural relation-
ship. In our model these effects might be provided by resid-
ual MSCs in the MSC-derived chondrocyte culture,
inducing rapid angiogenesis and making the graft viable.
As Genden and associates13 showed in 2003, the necessity
of re-epithelialization is highly important for graft integrity
and for protection against a fibroproliferative response of
the recipient. Additionally, we showed that long-segment
grafts need to be seeded with epithelial cells before ortho-
topic transplantation to avoid bacterial/fungal contamina-
tion. Compared with our previous technically demanding
method of direct graft revascularization,6 the approach de-
scribed here makes the tracheal reconstruction much more
practicable and reproducible but nevertheless with an out-
standing outcome.
Gathering knowledge and information regarding the
strain abilities of a tracheal graft were disappointing.14,15
Only a few publications were helpful when designing the
tensile test; however, in vitro and in vivo findings did not
correlate with each other. Our strain tests showed no differ-
ence in biomechanical properties between decellularized
scaffolds before implantation, scaffolds seeded with both
cell types 60 days after implantation, and normal trachea.
Therefore one can assume that there would be no collapse
of such grafts. However, our tensile-testing device provided
only longitudinal forces, and therefore the true test followed
in vivo, when multidirectional forces were applied. Under
these conditions, grafts with no cells or only 1 cell type
failed to retain functional strength, leading to incompetent
airways.
In conclusion, this experimental study demonstrated for
the first time the necessity of both MSC-derived chondro-
cytes and epithelial cells to obtain a functional and proper
long-segment tracheal graft with clinical effect. These
findings and the applied method of tissue engineering
will help forward the reconstruction of the trachea in
human subjects. Further studies are required to elucidate
the angiogenesis mechanisms and interactions between
residual MSCs.442 The Journal of Thoracic and Cardiovascular SurgReferences
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Dr Yolonda Colson (Boston, Mass). I have no conflicts.
You are to be congratulated on doing an amazing job in getting
this to actually work, and I think that you have defined a very nice
clinical problem that currently does not have a great solution.
Having said that, I think there are a lot of obvious questions in
terms of longer-term follow-up and analysis. I have several
questions.
You have 4 different groups that fail for different reasons, except
group 4, which does well. Were those groups done sequentially,
meaning did you do all the animals in group 1, all the animals in
group 2, and so, on so that there is a learning curve in terms of
infection and how you do it, or were they randomized?
Dr Go. Yes, it was randomized.
Dr Colson. Therefore there were some in the different groups
done after your success in group 4?
Dr Go. Exactly.
Dr Colson. I read the article that you have submitted, and you
also talk about there being no evidence of rejection or reaction.
What was done to actually know that other than grossly looking
at it because you did a lot of biopsies and obtained a lot of bloodery c February 2010
Go et al Evolving Technology/Basic Sciencesamples in the article that you did not talk about here. Second, the
animals in group 4 were all killed at 60 days, which is a little less
than 1 month after group 3. Is 60 days significant? In terms of lon-
ger-term follow-up, does that help us clinically?
Dr Go. To answer the first question, we took blood samples for
analysis, as I mentioned in the presentation, to determine, for exam-
ple, swine leukocyte antigen and other information and the C-reac-
tive protein level. As for the rejection, I just mentioned the swine
leukocyte antigen.
Excuse me, what was the second question?
Dr Colson. The animals in group 4 were killed at 60 days rou-
tinely rather than seeing what their long-term
Dr Go. To my knowledge, 1 month in the pig is comparable
with 6 months in a human subject, which means 60 days in
a pig translates to 360 days in a human subject. However, this
is just follow-up for the middle term. I would not say this is for
the long-term result.The Journal of Thoracic and CaDr Colson. Have you seen that in your patient whose case was
published in Lancet?
Dr Go. Yes. Actually, after 3 months of follow-up, she is doing
fine.
Dr Frank C. Detterbeck (New Haven, Conn). You replaced
a 6-cm segment of trachea?
Dr Go. Yes.
Dr Detterbeck. Tell me about the respiratory endothelium. It
seems like that has been the problem with longer-segment tracheal
replacement. Unless I missed it, you were seeding with chondro-
cytes primarily, right?
Dr Go. Sorry, I did not hear the question.
Dr Detterbeck. You seeded your bioengineered grafts with
chondrocytes.
Dr Colson. On the outside and epithelium on the inside.
Dr Detterbeck. Epithelium on the inside. Okay. I missed that
part. Thank you.rdiovascular Surgery c Volume 139, Number 2 443
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